Novel medicines focused on the BIG Axis

We are advancing innovative therapies across our internal and affiliate pipelines.

Our Affiliates pipeline

The Affiliates pipeline includes seven clinical-stage platforms, including one FDA cleared product, a second product candidate currently pursuing FDA clearance, and several other novel preclinical programs that have been developed in collaboration with some of the world's leading scientific experts

Brain/Nervous System

TRIAL PHASE
AFFILIATE FOCUS PRTC
OWNERSHIP
PRECLINICAL PHASE 1 PHASE 2 PHASE 3/
PIVOTAL
FILING FDA CLEARED
Schizophrenia, Dementia-related psychosis, Pain
20.4% (Karuna)R%
MDD
34.9% (Akili)%
Pediatric ADHD
34.9% (Akili)%
MDD, MS
34.9% (Akili)%
Autism
34.9% (Akili)%
Depression Screening
55.9% (Sonde)%

Immune System

TRIAL PHASE
AFFILIATE FOCUS PRTC
OWNERSHIP
PRECLINICAL PHASE 1 PHASE 2 PHASE 3/
PIVOTAL
FILING FDA CLEARED
AML
30.2% (Vor)%
Solid Tumors
53.3% (Vedenta)%
Food Allergy
53.3% (Vedanta)%
IBD
53.3% (Vedanta)%
rCDI
53.3% (Vedanta)%
Skin Rejuvenation
77.9% (Follica) R%
Androgenic Alopecia
77.9% (Follica) R%
IC/BPS
82.7% (Alivio)%
IBD
82.7% (Alivio)%
Distal Colistis, Pouchistis
82.7% (Alivio)%
Solid , Autoimmune Disorders
100% (Internal)%
Solid Tumors, Autoimmune Disorders
100% (Internal)%
Lymphedema
100% (Internal)%

GI System

TRIAL PHASE
AFFILIATE FOCUS PRTC
OWNERSHIP
PRECLINICAL PHASE 1 PHASE 2 PHASE 3/
PIVOTAL
FILING FDA CLEARED
IBD
22.3% (Gelesis)R%
NASH/NAFLD
22.3% (Gelesis)R%
Weight Management in T2D/Prediabetes
22.3% (Gelesis)R%
CIC
22.3% (Gelesis)R%
Overweight and Obesity
22.3% (Gelesis)%
Metabolic Disorders
72.9% (Entrega)%

Brain / Nervous System

Schizophrenia, Dementia-related psychosis, Pain
20.4% (Karuna)R%
2
MDD
34.9% (Akili)%
Preclinical
Pediatric ADHD
34.9% (Akili)%
3
MDD, MS
34.9% (Akili)%
2
Autism
34.9% (Akili)%
2
Depression Screening
55.9% (Sonde)%
1

Immune System

AML
30.2% (Vor)%
Preclinical
Solid Tumors
53.3% (Vedenta)%
1
Food Allergy
53.3% (Vedanta)%
1
IBD
53.3% (Vedanta)%
1
rCDI
53.3% (Vedanta)%
2
Skin Rejuvenation
77.9% (Follica) R%
2
Androgenic Alopecia
77.9% (Follica) R%
2
IC/BPS
82.7% (Alivio)%
Preclinical
IBD
82.7% (Alivio)%
Preclinical
Distal Colistis, Pouchistis
82.7% (Alivio)%
Preclinical
Solid , Autoimmune Disorders
100% (Internal)%
Preclinical
Solid Tumors, Autoimmune Disorders
100% (Internal)%
Preclinical
Lymphedema
100% (Internal)%
1

GI System

IBD
22.3% (Gelesis)R%
Preclinical
NASH/NAFLD
22.3% (Gelesis)R%
Preclinical
Weight Management in T2D/Prediabetes
22.3% (Gelesis)R%
2
CIC
22.3% (Gelesis)R%
2
Overweight and Obesity
22.3% (Gelesis)%
3
Metabolic Disorders
72.9% (Entrega)%
Preclinical

*PureTech owns 7,395,397 shares of Karuna, which is equal to approximately 32.8% of the outstanding shares of Karuna.

**PureTech owns 9,800,396 shares of resTORbio, which is equal to approximately 27.8% of the outstanding shares of resTORbio.

 

Collaborating with Industry Pioneers Across Our Affiliates and Internal Pipelines

Amgen Novartis Lilly Merck Boehringer Ingelheim Bristol-Myers Squibb Janssen Roche

DISCOVERY REINVENTED

  • Aging related immune disorders
  • Gut/Immune Ecosystem
  • Severe and Chronic Mental Health